Group 1 - The "Good Hope Science Salon" held in Shanghai focused on the theme "The Path of Scientific Research: From Pathogen Basic Research to Infectious Disease Prevention and Control Applications," gathering over 130 experts from life sciences, technology enterprises, and investment institutions to discuss the latest research achievements and investment logic in the biopharmaceutical industry [1] - Gao Fu, an academician from the Chinese Academy of Sciences, emphasized the importance of understanding basic research to guide vaccine development, including the types of peptides or proteins to use [1] - Gao also highlighted the issue of "information viruses" and "information epidemics," which complicate public access to reliable information, stressing the need for effective science communication as a societal vaccine [1] Group 2 - Tang Chang, General Manager of Changzhou Longzang Biotechnology Co., Ltd., discussed the role of vaccine adjuvants in vaccine development, particularly their suitability for special populations such as children and the elderly, and the need for discovering better adjuvants [1] - Liu Kefang, Chairman of Beijing Xinzhi Biopharmaceutical Co., Ltd., noted the advantages of AI in integrating large datasets to aid in the design of immune responses, thereby supporting the development of broad-spectrum influenza vaccines [1]

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is under pressure in 2024, with performance still in a bottoming process. The short-term landscape shows a high proportion of Me-too pipelines, leading to intense competition among similar products. Companies are facing a challenging environment and are actively adjusting their pipeline strategies to focus on high-barrier, well-competitive multi-valent products. The continuous integration of AI technology is expected to gradually empower vaccine research and development. Based on three driving factors—policy, demand, and technology—the long-term outlook for the vaccine industry remains positive, maintaining the "Overweight" rating [10][31][32]. Market Performance - Last week, the vaccine sector rose by 0.67%, which is relatively modest compared to other segments. The overall pharmaceutical and biological sector reported a 1.06% increase, while the vaccine sector has seen a cumulative decline of 5.66% since the beginning of 2025 [4][5][10]. Valuation Metrics - The vaccine sector's PE (ttm) was 34.02X, up by 0.23X week-on-week, with a one-year maximum of 41.43X and a minimum of 19.57X. The PB (lf) was 1.88X, also up by 0.01X week-on-week, with a one-year maximum of 2.91X and a minimum of 1.62X. The PE is at the 15.83% percentile and the PB at the 2.08% percentile over the past decade. The valuation premium of the vaccine sector relative to the CSI 300 is 169.54% [6][10][21]. Industry Dynamics and Company Announcements - Key developments include: 1. Kanglaisheng reported a 50.24% decline in revenue for 2024, with a total profit loss of 3.52 billion yuan, primarily due to increased R&D and depreciation costs [7][28]. 2. The company’s nine-valent HPV vaccine has completed the first analysis of its Phase III clinical trial, meeting the statistical criteria for efficacy [28]. 3. Kangtai Biotech received a summary report for its adsorbed tetanus vaccine's Phase I/III clinical trial, indicating good safety and immunogenicity [28]. 4. CloudTop's new mRNA personalized tumor therapeutic vaccine EVM16 has completed its first patient dosing, marking a significant step in AI-driven vaccine development [10][28].